196613-57-7

Basic information

• Product Name: 1-Boc-hexahydro-1H-azepin-4-amine
• Synonyms: 4-AMINO-AZEPANE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1H-AZEPINE-1-CARBOXYLIC ACID, 4-AMINOHEXAHYDRO-, 1,1-DIMETHYLETHYL ESTER;1-N-BOC-HEXAHYDRO-1H-AZEPIN-4-AMINE;1-Boc-hexahydro-1H-azepin-4-amine;4-Amino-1-Boc-hexahydro-1H-azepine;tert-Butyl 4-aminoazepane-1-carboxylate;Tert-butyl 4-aminoazepane-1-carboxyalte;1-N-BOC-HEXAHYDRO-1H-AZEPIN-4-
• CAS NO: 196613-57-7
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• EINECS: 200-110-4
• Product Categories: pharmacetical
• Mol File: 196613-57-7.mol

Chemical Properties

• Boiling Point: 296 ºC
• Flash Point: 133 ºC
• Appearance: /
• Density: 1.020
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.41±0.20(Predicted)
• CAS DataBase Reference: 1-Boc-hexahydro-1H-azepin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-hexahydro-1H-azepin-4-amine(196613-57-7)
• EPA Substance Registry System: 1-Boc-hexahydro-1H-azepin-4-amine(196613-57-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 196613-57-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Boc-hexahydro-1H-azepin-4-amine is used as a reagent for the preparation of piperidinyl-nicotinamides, which are selective somatostatin receptor subtype 5 antagonists (SSTR5 antagonists). These antagonists have potential applications in the treatment of various disorders, including neuroendocrine tumors and other conditions where somatostatin receptor regulation is crucial. The Boc-protected amine group in 1-Boc-hexahydro-1H-azepin-4-amine allows for selective reactions and the synthesis of desired piperidinyl-nicotinamide derivatives with improved pharmacological properties.

InChI:InChI=1/C11H22N2O2/c1-11(2,3)15-10(14)13-7-4-5-9(12)6-8-13/h9H,4-8,12H2,1-3H3

Upstream product

• 878630-66-1 tert-butyl 4-(benzylamino)azepane-1-carboxylate 
• 188975-88-4 tert-butyl 4-oxoazepane-1-carboxylate 

Downstream Products

• 878630-96-7 (R)-tert-butyl 4-(benzyloxycarbonylamino)azepane-1-carboxylate 
• 878630-67-2 1,1-dimethylethyl 4-[(N-{[(phenylmethyl)oxy]carbonyl}-L-leucyl)amino]hexahydro-1H-azepine-1-carboxylate 
• 878630-97-8 4-(benzyloxycarbonylamino)azepane 
• 1338718-15-2 (R)-benzyl 1-(4-(5-tert-butoxycarbonyl-amino-2-bromothiazole-4-carboxamido)-1-methyl-1H-pyrazol-5-yl)azepan-4-ylcarbamate 
• 1338715-74-4 (R)-5-amino-N-(5-(4-aminoazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,4-difluorophenyl)thiazole-4-carboxamide 
• 1338718-77-6 [(R)-1-(4-{[5-tert-butoxycarbonylamino-2-(2,4-difluoro-phenyl)-thiazole-4-carbonyl]-amino}-2-methyl-2H-pyrazol-3-yl)-perhydro-azepin-4-yl]-carbamic acid benzyl ester 
• 1338718-79-8 [(R)-1-(4-{[5-tert-butoxycarbonylamino-2-(3-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-2-methyl-2H-pyrazol-3-yl)-perhydro-azepin-4-yl]-carbamic acid benzyl ester 
• 1338715-89-1 (R)-5-amino-N-(5-(4-aminoazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2-(trifluoromethyl)phenyl)thiazole-4-carboxamide 
• 1338718-81-2 [(R)-1-(4-{[5-tert-butoxycarbonylamino-2-(2-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-2-methyl-2H-pyrazol-3-yl)-perhydro-azepin-4-yl]-carbamic acid benzyl ester 
• 1338716-22-5 (R)-5-amino-N-(5-(4-aminoazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(5-cyclopropyl-2-fluoro-3-methylphenyl)thiazole-4-carboxamide 
• 1338718-86-7 (R)-tert-butyl 4-(5-(4-Cbz-aminoazepan-1-yl)-1-methyl-1H-pyrazol-4-ylcarbamoyl)-2-(5-cyclopropyl-2-fluoro-3-methylphenyl)thiazol-5-ylcarbamate 
• 1338716-37-2 (R)-5-Amino-N-(5-(4-aminoazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(4-methoxy-2-(trifluoromethyl)phenyl)thiazole-4-carboxamide 
• 1338719-22-4 (R)-tert-butyl 4-(benzyloxycarbonylamino)azepane-1-carboxylate 
• 1338719-23-5 tert-butyl (S)-4-(((benzyloxy)carbonyl)amino)azepane-1-carboxylate 

Relevant articles and documents

INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF

Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME

A compound of formula (I) or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating non-insulin dependent type 2 diabetes, ins

BRADYKININ 1 RECEPTOR ANTAGONISTS

The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.

NOVEL COMPOUNDS

This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted amino -azepines, according to Formula (I). Specifically, the invention is directed to compounds according to Formula (I), wherein: R1 is optionally substituted C3-7cycloalkyl, optionally substituted C3-7cycloalkenyl, optionally substituted Het-C3-7alkyl, optionally substituted Het-C3-7-alkenyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, or optionally substituted indenyl; R2 is H, optionally substituted C1-6alkyl, C3-6cycloalkyl-C0-6alkyl, Ar-C0-6alkyl, or Het-C0-6alkyl; each R3 is independently H, optionally substituted C1-8alkyl, optionally substituted C2-8alkenyl, optionally substituted C2-8alkynyl, Het-C1-6 alkyl, optionally substituted C3-6cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, or optionally substituted C1-C6 alkoxy; R4 is H, or optionally substituted C1-C4 alkyl; R5 is H, optionally substituted C1-8alkyl, optionally substituted C2-8alkenyl, optionally substituted C2-8alkynyl, optionally substituted C3-6cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; R6 is H or C1-6alkyl; and X is SO2, CO, CH2, or CONH, and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof.

NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY

The invention relates to novel antibacterial compounds of formula (I).